Global Hypertensive Heart Diseases Market, Size, Share, Analysis Report & Forecast to 2026

The global hypertensive heart diseases market is anticipated to grow at a CAGR of around 3.5% during the forecast period (2021-2027). The prevalence of hypertensive heart disease in North America is the major factor driving the growth of the region. The growing aging population in the US accelerating the demand for hypertensive heart disease treatments and drugs. As per the Urban Institutes, the aging population over 65 in America is expected to be double over the next 40 years, reaching 80 million in 2040. Hypertension is the major cause of heart disease in the US population. In 2018, nearly half a million deaths in the US included hypertension as a primary or contributing cause as per the CDC estimates. According to the CDC, hypertension in the US costs around $48.6 billion every year. This cost includes the cost related to the medication, healthcare services, and other related healthcare services.

Free Sample Copy @ https://www.omrglobal.com/request-sample/hypertensive-heart-disease-market

The global hypertensive heart diseases market is anticipated to grow at a CAGR of around 3.5% during the forecast period (2021-2027). Hypertensive heart diseases refer to heart failure, CAD (coronary artery disease), and thickening of heart muscles, due to high blood pressure. Other diseases caused by high blood pressure include stroke, ischemic heart disease, peripheral artery disease, aneurysms, and other kidney diseases. The rising prevalence of hypertensive heart diseases & awareness program by government organizations, and high global healthcare expenditure is boosting the growth of hypertensive heart disease market. According to the American College of Cardiology, Cardiovascular disease (CVD) are the leading cause of death in the US, around 840,768 deaths (635,260 cardiac) in 2016 were due to CVDs. Whereas, according to the same source, every 40 seconds on an average, an American will have a stroke. About 795,000 Americans have a new or recurrent stroke annually. The high healthcare expenditure by the government is also playing an important role in the market growth. For instance, in 2018, $3.8 trillion were invested by the US government in healthcare, under which $194 billion or 5% of the healthcare spending has been invested in medical and R&D expenditure. The federal government contributed around 22.2% to Medical and Health R&D expenditures.

A Full Report of Global Hypertensive Heart Diseases Market is Available at:
https://www.omrglobal.com/industry-reports/hypertensive-heart-disease-market

The global Hypertensive heart diseases market is segmented based on diagnosis and therapeutics. Based on the diagnosis, the market is sub-segmented into electrocardiogram, echocardiogram, coronary angiography, and others (chest x-ray). Based on therapeutics, the global hypertensive heart diseases market is classified into drugs and surgery. The drug segment is further categorized into thiazide diuretics beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), calcium channel blockers, and others (renin inhibitors). Similarly, the surgery segment is further classified into coronary artery bypass surgery, transmyocardial laser revascularization, and heart transplant. Among the therapeutic segment, the surgery sub-segment is projected to grow at faster CAGR during the forecast period owing to the increasing surgical transplant procedure due to the rising prevalence of heart failures.

Global Hypertensive Heart Diseases Market – Segmentation
By Diagnosis
Electrocardiogram
Echocardiogram
Coronary Angiography
Others (Chest X-Ray)
By Therapeutics
Drugs
Thiazide Diuretics
Beta-Blockers
Angiotensin-Converting Enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARB)
Calcium Channel Blockers
Others (Renin Inhibitors)
Surgery
Coronary Artery Bypass Surgery
Transmyocardial Laser Revascularization
Heart Transplant

Global Hypertensive Heart Diseases Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles
Abbott Laboratories
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Boehringer Ingelheim International GmbH
Bayer AG
Eiger Biopharmaceuticals, Inc.,
Daiichi Sankyo Co., Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline PLC
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Lupin Pharmaceuticals, Inc.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi SA
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Co. Ltd.
United Therapeutics Corp.
Northern Therapeutics Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hypertensive-heart-disease-market

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com 
Contact no: +91 780-304-0404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.